A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
Juwhan ChoiJeong Eun LeeChang-Min ChoiIn Jae OhKye Young LeeTae Won JangSeung-Hyeun LeeEun Young KimDong Won ParkSun Hyo ParkSung-Yong LeePublished in: Thoracic cancer (2022)
Our study may extend the indications for third-generation EGFR-TKIs to treat patients with stage III NSCLC. Moreover, using this drug to treat stage III NSCLC would emphasize the value of mutation analysis and personalized medicine.
Keyphrases
- locally advanced
- small cell lung cancer
- phase ii
- rectal cancer
- clinical trial
- neoadjuvant chemotherapy
- squamous cell carcinoma
- open label
- radiation therapy
- epidermal growth factor receptor
- phase ii study
- phase iii
- advanced non small cell lung cancer
- tyrosine kinase
- brain metastases
- stem cells
- double blind
- placebo controlled
- lymph node